Cellectis
CLLS
$2.56
Share price
1.59%
Change (1 day)
31.28%
Change (1 year)
Categories
Cellectis (CLLS) - P/B ratio
P/B ratio as of May 2024 : 2.42
According to Cellectis's latest financial reports the company has a price-to-book ratio of 2.42.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Cellectis - P/B ratio (from 2013 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 2.90 | 272.73% |
| 2022-12-31 | 0.7771 | -52.03% |
| 2021-12-31 | 1.62 | -60.76% |
| 2020-12-31 | 4.13 | 96.75% |
| 2019-12-31 | 2.10 | 29.08% |
| 2018-12-31 | 1.63 | -54.2% |
| 2017-12-31 | 3.55 | 61% |
| 2016-12-31 | 2.20 | -40.83% |
| 2015-12-31 | 3.73 | -38.42% |
| 2014-12-31 | 6.05 | -68.6% |
| 2013-12-31 | 19.3 | |
| 2012-12-31 | N/A | |
| 2011-12-31 | N/A | |
| 2010-12-31 | N/A | |
| 2009-12-31 | N/A | |
| 2008-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Regeneron Pharmaceuticals REGN | 3.78 | 56.15% | 🇺🇸 USA |
 uniQure QURE | 1.03 | -57.44% | 🇳🇱 Netherlands |
 Novavax NVAX | -0.8453 | -134.93% | 🇺🇸 USA |